Amprius Technologies, Inc.

Fundamentals5.0
Price Action6.0
News Sentiment7.0
AI Rating
6.0

Key Drivers

  • Strong liquidity
  • Severe profitability
  • Reliance on financing

AI
AI Summary

6.0

AMPX has moved from a speculative R&D story to a commercialization inflection — management's >=$125M 2026 revenue target and Q4 adjusted EBITDA positivity mean the investment now hinges on converting product qualifications into repeatable SiCore-driven volume and NDAA-capable domestic production. If AMPX achieves a higher SiCore mix and consistent backlog-to-production cadence without heavy dilutive capex, upside is material; if not, continued negative FCF and missed conversions will likely trigger sharp multiple downside and equity raises.

GrowthOpportunity
ExecutionRisk
CashFlow‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

5.0

Key Financial Insights:

  • Strong liquidity
  • Severe profitability
  • Reliance on financing

AMPX has a solvent balance sheet with strong cash and low leverage but is burning cash through heavy operating losses and negative free cash flow while trading at rich valuation multiples inconsistent with fundamentals.

Overvalued
Solvent

Price Behavior

6.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Strong uptrend
  • Resistance cluster
  • Overbought risk

AMPX has ripped ~90% over the last month into a strong uptrend trading well above the ~$15 last-month SMA but faces resistance near $19–$20 and is vulnerable to sharp retracements after the rapid gain.

Bullish
Overbought
Support Level: $14.9–$16.3
Resistance Level: $19–$20

Very steep ~90% rise over the last month, raising short-term volatility risk

Sentiment & News

7.0

Key News Insights:

  • Revenue surge
  • Analyst upgrades
  • Insider selling

Amprius posted strong Q4 and FY25 revenue growth and beat guidance, sparking an 18.6% rally and analyst upgrades amid rising institutional interest but notable insider selling.

Hypergrowth
InsiderSales

Positive momentum from upside results and upgraded guidance should support further share-price gains short term, though insider sales add a cautionary risk factor